Table 1.
Baseline characteristics of the 91 patients
| Variables | 25(OH)D | 25(OH)D | All patients |
|---|---|---|---|
| <10 ng ml−1 | ≥10 ng ml−1 | ||
| n | 25 | 66 | 91 |
| Age, years | 17 (12–17) | 13 (10–17) | 14 (11–17) |
| Gender, n (%) | |||
| Boys | 13 (28) | 34 (72) | 47 (52) |
| Girls | 12 (27) | 32 (73) | 44 (48) |
| Ethnic origin, n (%) | |||
| White | 2 (7) | 27 (93) | 29 (32) |
| Other | 23 (37) | 39 (63) | 62 (68) |
| Bodyweight, kg | 52 (45–60) | 46 (29–59) | 50 (35–60) |
| BMI, kg m−2 | 21 (19–22) | 19 (17–23) | 20 (17–22) |
| HIV-1 viral load, log10 copies ml−1 | 1.6 (1.6–3.6) | 1.6 (1.6–2.4) | 1.6 (1.6–2.7) |
| CD4, cells mm−3 | 650 (462–832) | 754 (506–1073) | 703 (487–984) |
| Current ARV therapy duration, years | 1.6 (0.5–2.3) | 2 (1.3–2.3) | 2 (1.1–2.3) |
| Combined ARV drug, n (%) | |||
| PI + 2 NRTI | 16 (27) | 44 (73) | 60 (66) |
| NNRTI + 2 NRTI | 4 (31) | 9 (69) | 13 (14) |
| NNRTI + PI + II | 2 (25) | 6 (75) | 8 (9) |
| PI + II | 1 (33) | 2 (67) | 3 (3) |
| PI + NNRTI | 1 (50) | 1 (50) | 2 (2) |
| No treatment | 1 (20) | 4 (80) | 5 (5) |
| 25(OH)D, ng ml−1 | 7 (6–8) | 14 (12–18) | 12 (9–17) |
| Total corrected calcium, mmol l−1 | 2.3 (2.3–2.4) | 2.3 (2.3–2.4) | 2.3 (2.3–2.4) |
| Serum phosphate, mmol l−1 | 1.2 (1.2–1.4) | 1.3 (1.2–1.5) | 1.3 (1.2–1.5) |
| Serum magnesium, mmol l−1 | 0.9 (0.9–1.0) | 0.9 (0.9–1.0) | 0.9 (0.9–1.0) |
Data are described as median (IQR). 25(OH)D, 25-hydroxycholecalciferol (calcidiol); ARV, antiretroviral; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; II, integrase inhibitor; PI, protease inhibitor.